Risk of thromboembolism in patients with metastatic renal cell carcinoma treated with combination‐based immunotherapy

Key Points

• This research aims to evaluate the risk of thromboembolism in patients with metastatic renal cell carcinoma undergoing combination-based immunotherapy.
• Utilized propensity score matching to analyze the risk of thromboembolism among patients.
• Examined disease and outcome definitions to ensure accurate data categorization.
• Provided supporting data available upon request.
• Detailed findings on thromboembolism risk during immunotherapy were articulated.
• Specific event rates and statistical measures were not disclosed in the abstract.

Abstract